Functional Assays

The PDE9A Assay Kit is designed for identification of PDE9A inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE9A to the binding agent. The key to the PDE9A Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE9A reactions. First, the fluorescently labeled cGMP is incubated with a sample containing PDE9A for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.

The PDE1C Assay Kit is designed for identification of PDE1C inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE1C to the binding agent. The key to the PDE1C Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE1C reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE1C for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.

The PDE3B Assay Kit is designed for identification of PDE3B inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE3B to the binding agent. The key to the PDE3B Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE3B reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE3B for 1 hour. Second, binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader equipped for the measurement of fluorescence polarization.

The PDE4C1 Assay Kit is designed for identification of PDE4C1 inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE4C1 to the binding agent. The key to the PDE4C1 Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE4C1 reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE4C1 for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.

The PDE10A1 Assay Kit is designed for identification of PDE10A1 inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE10A1 to the binding agent. The key to the PDE10A1 Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE10A1 reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE10A1 for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.

The PDE10A2 Assay Kit is a fluorescence polarization (FP), homogeneous, 96-well assay kit designed for the screening and profiling of PDE10A2 (Phosphodiesterase 10A2) inhibitors. This assay takes advantage of a specific fluorescent phosphate-binding nanoparticle. The kit contains enough purified recombinant PDE10A2, fluorescent probe, PDE assay buffer, Binding Agent, and diluent for 100 reactions. The assay uses a fluorescein-labeled cyclic adenosine monophosphate (cAMP-FAM for PDE10A2), in which the phosphate group is engaged within the cyclic nucleotide. This is a very small molecule that rotates fast (low FP). PDE10A2 catalyzes the hydrolysis of the phosphodiester bond in the cyclic nucleotide and frees the phosphate group. In a second step the free phosphate group is recognized by a specific phosphate-binding nanobead (Binding Agent) leading to the formation of a large complex, with restricted movement (high FP). FP is proportional to PDE10A2 activity.

The PDE11A Assay Kit is designed for identification of PDE11A inhibitors using fluorescence polarization. The assay is based on the binding of a fluorescent nucleotide monophosphate generated by PDE11A to the binding agent. The key to the PDE11A Assay Kit is the specific binding agent. Using this kit, only two simple steps on a microtiter plate are required for PDE11A reactions. First, the fluorescently labeled cAMP is incubated with a sample containing PDE11A for 1 hour. Second, a binding agent is added to the reaction mix to produce a change in fluorescent polarization that can then be measured using a fluorescence reader.

Please note this product may be subject to fees, we invite you to contact your local office. The TCF/LEF Reporter kit is designed for monitoring the activity of Wnt / β-catenin signaling pathway in the cultured cells. The kit contains transfection-ready TCF/LEF luciferase reporter vector, which is a Wnt pathway-responsive reporter. This reporter contains a firefly luciferase gene under the control of multimerized TCF/LEF responsive element located upstream of a minimal promoter. The TCF/LEF reporter is premixed with constitutively-expressing Renilla luciferase vector that serves as internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical to determining pathway sp

The PDE4D cell-based activity assay is designed for screening inhibitors of PDE4D7 in cultured cells. The assay is based on transfecting cells with the CRE luciferase reporter. CRE reporter contains the firefly luciferase gene under the control of cAMP response element (CRE). Elevation of intracellular cAMP activates CRE binding protein (CREB) to bind CRE and induce the expression of luciferase. When cells transiently transfected with CRE reporter are activated by forskolin, the intracellular level of cAMP is upregulated, which induces the expression of CRE luciferase reporter. However, when cells are co-transfected with PDE4D7 expression vector and CRE reporter, the level of forskolin-induced cAMP is reduced, resulting in lower expression level of luciferase. When cells are treated with PDE4D inhibitor to inhibit PDE4D7 activity, cAMP level is restored, resulting in higher luciferase activity.